当前抗病毒治疗对乙型肝炎病毒相关的肝细胞癌的二级预防

StephenW

Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapies
Jonggi Choi  1 , Young-Suk Lim  1
Affiliations
Affiliation

    1
    Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

    PMID: 33502828 DOI: 10.1002/kjm2.12364

Abstract

Over the past decades, marked advancement has been made in the prevention and treatment of hepatitis B virus (HBV) infection. Due to highly effective antiviral therapies for chronic hepatitis B (CHB), long-term clinical outcomes in patients with CHB has also been dramatically improved. However, current antiviral therapies for CHB cannot completely abolish the risk of hepatocellular carcinoma (HCC). In addition, current treatment guidelines for CHB should be interpreted with caution given that HBV-associated hepatocarcinogenesis could be underway in patients who are not eligible for antiviral therapies by current guidelines. Therefore, efforts to reconcile treatment guidelines with recent clinical evidence should be made for reducing further development of HCC. In this article, we review the secondary prevention of HBV-related HCC with current antiviral therapies.

Keywords: disease burden; hepatitis B virus; hepatocellular carcinoma.

© 2021 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.

StephenW

当前抗病毒治疗对乙型肝炎病毒相关的肝细胞癌的二级预防
崔钟基1，林淑淑1
隶属关系
联系

    1个
    韩国首尔蔚山大学医学院牙山医学中心消化内科。

    PMID：33502828 DOI：10.1002 / kjm2.12364

抽象

在过去的几十年中，在预防和治疗乙型肝炎病毒（HBV）感染方面取得了显着进步。由于针对慢性乙型肝炎（CHB）的高效抗病毒治疗，CHB患者的长期临床疗效也得到了显着改善。但是，当前针对CHB的抗病毒治疗不能完全消除肝细胞癌（HCC）的风险。此外，鉴于当前指南不适合抗病毒治疗的患者中可能正在进行HBV相关的肝癌发生，因此应谨慎解释当前的CHB治疗指南。因此，应努力使治疗指南与最近的临床证据相一致，以减少肝癌的进一步发展。在本文中，我们回顾了当前抗病毒治疗对HBV相关HCC的二级预防。

关键词：疾病负担乙型肝炎病毒;肝细胞癌。

©2021作者。 John Wiley＆Sons Australia代表高雄医科大学出版的《高雄医学杂志》。

StephenW

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/kjm2.12364